As of 11:06 on April 11, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 1.36%, the constituent stocks Akeso Biologics (09926) rose 10.45%, East Sunshine Changjiang Pharmaceutical (01558) rose 5.68%, Innovent Biologics (01801) rose 5.15%, Ascentage Pharma-B (06855), Genting Xinyao-B (01952) and other stocks followed suit. Hong Kong Pharmaceutical ETF (159718) rose 1.55% to the latest price of $0.65. In the long run, as of April 10, 2025, Hong Kong stock pharmaceutical ETFs have risen by 17.30% in the past three months, ranking 2/4 of comparable funds.

In terms of liquidity, Hong Kong stock pharmaceutical ETFs changed hands by 23.64% intraday, with a turnover of 49.587 million yuan, and the market was actively trading. In the long run, as of April 10, the average trading volume of Hong Kong stock pharmaceutical ETFs in the past one week was 81.9979 million yuan.

In terms of scale, the scale of Hong Kong-listed pharmaceutical ETFs has increased by 9.6159 million yuan in the past two weeks, achieving significant growth, and the new scale ranks 1/4 of comparable funds.

In terms of shares, the latest share of Hong Kong stock pharmaceutical ETFs reached 325 million shares, a new high in nearly January.

From the perspective of net inflow of funds, Hong Kong stock pharmaceutical ETFs have received continuous net inflows in the past 4 days, with the highest net inflow of 16.6887 million yuan in a single day, with a total of 36.6776 million yuan and an average daily net inflow of 9.1694 million yuan.

As of 11:05 on April 11, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) fell by 1.31%. In terms of constituent stocks, Yirui Technology (688301) led by 3.84%, Antu Biotechnology (603658) rose 0.38%, and Xingqi Eye Medicine (300573) rose 0.29%; United Imaging Medical (688271) led the decline by 3.46%, Haisco (002653) fell by 2.83%, and Aimec (300896) fell by 2.40%. Medical Innovation ETF (516820) fell 0.90%, with the latest price of 0.33 yuan. In the long run, as of April 10, 2025, the medical innovation ETF has risen by 6.05% in the past 3 months.

In terms of liquidity, the medical innovation ETF changed hands by 1.31% intraday, with a turnover of 21.7142 million yuan. In the long run, as of April 10, the average trading volume of medical innovation ETF in the past one week was 86.8731 million yuan.

In terms of scale, the latest scale of medical innovation ETF reached 1.667 billion yuan.

In terms of fund inflow, medical innovation ETF has had a net inflow of funds for 3 days in the past 4 trading days, with a total of 35.5464 million yuan and an average daily net inflow of 8.8866 million yuan.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 10.9487 million yuan, and the latest financing balance reached 76.2824 million yuan.

On April 10, the "Innovation Partnership Through Train" of Haidian District's Pharmaceutical Industry and Haidian Pharmaceutical and Medical Equipment Products Exhibition was held. As a gathering place for scientific and technological innovation resources, Haidian District focuses on the integrated development of "AI + medicine and health", and has built a full-chain industrial ecology of "R&D-clinical-transformation" driven by original innovation. The region has gathered innovative pharmaceutical companies such as Zhenzhi Medical and Peking University Weixin, as well as top medical institutions such as Peking University Medical and 301 Hospital, forming a closed-loop system from basic research to clinical application.

On the same day, the Shanghai Municipal Food and Drug Administration announced that the State Medical Products Administration approved the marketing of Poperdacoyl Injection (trade name: Xinjiu Gel) declared by Shanghai Xinzhi Pharmaceutical Technology Co., Ltd. through the priority review and approval procedure for the treatment of adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency). This is the first hemophilia B gene therapy drug, and it is also the third domestic Class 1 innovative drug approved for marketing in Shanghai this year.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of March 31, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are WuXi Biologics (02269), BeiGene (06160), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), Sino Biopharma (01177), CSPC Pharmaceutical Group (01093), Zai Lab (09688), Ali Health (00241), and Hansoh Pharma ( 03692), the top 10 weighted stocks accounted for 59.76% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of March 31, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Mindray Medical (300760), Aier Ophthalmology (300015), United Imaging Medical (688271), Kelun Pharmaceutical (002422), Huadong Medicine (000963), Changchun High-tech (000661), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.49%.